Immunovant
Claudia Jacobs, Ph.D. is the Vice President of CMC Project Management, Operations and Clinical Supply at Immunovant. Prior to joining Immunovant she spent over 15 years at Eli Lilly & Company where she held numerous roles in product development in CMC, Clinical Trial Materials Manufacturing and Operations, Clinical Supply and Quality roles, supporting early and late phase program as well as launching products to market.
Most recently Claudia was a consultant for biotechnology start-up companies as CMC Project Manager, CMC Development Lead, and Quality Assurance Head for early phase programs small and large molecules.
Claudia obtained her Pharmacy Degree from the University of Hamburg, Germany and earned her Ph.D. in Pharmaceutical Technology from The Free University of Berlin, Germany.
This person is not in any offices
Immunovant
6 followers
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.